In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene

Cancer Research

Volumn 60, Issue 14, 2000, Pages 3813-3822

  Erbs, Philippe ^a   Regulier, Etienne ^a   Kintz, Jacqueline ^a   Leroy, Pierre ^a   Poitevin, Yves ^a   Exinger, Françoise ^b   Jund, Richard ^b   Mehtali, Majid ^c  

^a TRANSGENE S A   (France)

^b HÔPITAL CIVIL   (France)

^c CRUCELL HOLLAND BV   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; CHIMERIC PROTEIN; CYTOSINE DEAMINASE; FLUOROURACIL; FLUOROURIDINE 5' MONOPHOSPHATE; UNCLASSIFIED DRUG; URACIL PHOSPHORIBOSYLTRANSFERASE;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GENETICS; CANCER THERAPY; CATALYSIS; CELL KILLING; CONTROLLED STUDY; EXPERIMENTAL NEOPLASM; FUSION GENE; GENE THERAPY; GENE TRANSFER; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SACCHAROMYCES CEREVISIAE; SUICIDE GENE;

ADENOVIRIDAE; ANIMALS; ARTIFICIAL GENE FUSION; CYTOSINE DEAMINASE; FLUCYTOSINE; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; NEOPLASMS; NUCLEOSIDE DEAMINASES; PENTOSYLTRANSFERASES; PRODRUGS; RATS; RECOMBINANT FUSION PROTEINS; SACCHAROMYCES CEREVISIAE; TIME FACTORS; TRANSDUCTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 0034660858     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Drug sensitivity ("suicide") genes for selective cancer chemotherapy
2. Prodrugs in cancer chemotherapy
3. The choice of prodrugs for gene directed enzyme prodrug therapy of cancer
4. Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumors
5. Prodrug activated gene therapy: Involvement of an immunological component in the "bystander effect"
6. Ganciclovir chemoablation of herpes thymidine kinase suicide gene-modified tumors produces tumor necrosis and induces systemic immune responses
7. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: Paradigm for a prospective cancer control strategy
8. The "bystander effect": Tumor regression when a fraction of the tumor mass is genetically modified
9. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV-TK retroviral gene therapy
10. Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins
11. Lack of bystander killing in herpes simplex virus thymidine kinase-transduced colon cell lines due to deficient connexin43 gap junction formation
12. Intercellular communication mediates the bystander effect during herpes simplex thymidine kinase/ganciclovir-based gene therapy of human gastrointestinal tumor cells
13. Cancer gene therapy: A bystander effect using the gap junctional pathway
14. The metabolism of 5-fluorocytosine-2-14-C and of cytosine-14-C in the rat and the disposition of 5-fluorocytosine-2-14-C in man
15. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: A new negative selection system
16. A first step in the development of gene therapy for colorectal carcinoma: Cloning, sequencing, and expression of Escherichia coli cytosine deaminase
17. In vivo adenovirus-mediated gene transfer of the Escherichia coli cytosine deaminase gene to human colon carcinoma-derived tumors induces chemosensitivity to 5-fluorocytosine
18. In vivo gene therapy for α-fetoprotein producing hepatocellular carcinoma by adenovirus-mediated transfer of cytosine deaminase gene
19. In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase
20. Enzyme/prodrug gene therapy approach for breast cancer using a recombinant adenovirus expressing Escherichia coli cytosine deaminase
21. Gene therapy for cancer using tumour-specific prodrug activation
22. Adenovirus-mediated transduction of Escherichia coli uracil phosphoribosyltransferase gene sensitizes cancer cells to low concentrations of 5-fluorouracil
23. Genetic and physiological aspects of resistance to 5-fluoropyrimidines in Saccharomyces cerevisiae
24. The FUR1 gene of Saccharomyces cerevisiae: Cloning, structure and expression of wild type and mutant alleles
25. Characterization of the Saccharomyces cerevisiae FCY1 gene encoding cytosine deaminase and its homologue FCA1 of Candida albicans
26. Adenoviral vectors for gene transfer
27. A system of shuttle vectors and yeast strains designed for efficient manipulation of DNA in Saccharomyces cerevisiae
28. Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli
29. In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deleted
30. Generation of 5-fluorouracil from 5-fluorocytosine by monoclonal antibody-cytosine deaminase conjugates
31. Superiority of yeast over bacterial cytosine deaminase for enzyme/prodrug gene therapy in colon cancer xenografts
32. Enzyme/prodrug therapy for head and neck cancer using a catalytically superior cytosine deaminase
33. The pharmacology of the fluoropyrimidines
34. Concomitant expression of E. coli cytosine deaminase and uracil phosphoribosyltransferase improves the cytotoxicity of 5-fluorocytosine
35. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: Significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase
36. Enzyme/prodrug gene therapy: Comparison of cytosine desaminase/5-fluorocytosine versus thymidine kinase/ganciclovir enzyme/prodrug systems in a human colorectal carcinoma cell line
37. Comparison of the effects of three different toxin genes and their levels of expression on cell growth and bystander effect in lung adenocarcinoma
38. Loss of tumor thymidine kinase activity in vivo following 5-fluorouracil (FUra) treatment by incorporation of FUra into RNA
39. Radiosensitizing nucleosides
40. Radiosensitization by 5-fluorocytosine of human colorectal carcinoma cells in culture transduced with cytosine deaminase gene
41. Virally directed cytosine deaminase/5-fluorocytosine gene therapy enhances radiation response in human cancer xenografts